SUPERNUS PHARMACEUTICALS, INC. - 8-K Filing
Supernus Pharmaceuticals receives seven years of FDA orphan-drug exclusivity for ONAPGO and submits sNDA for second supplier. (Items: 9.01 Financial Statements and Exhibits)
Tickers: $SUPN
Supernus Pharmaceuticals receives seven years of FDA orphan-drug exclusivity for ONAPGO and submits sNDA for second supplier. (Items: 9.01 Financial Statements and Exhibits)
Tickers: $SUPN